Originalspråk | engelska |
---|---|
Tidskrift | Atherosclerosis |
Volym | 253 |
Sidor (från-till) | 281-344 |
Antal sidor | 64 |
ISSN | 0021-9150 |
DOI | |
Status | Publicerad - okt 2016 |
MoE-publikationstyp | A1 Tidskriftsartikel-refererad |
Vetenskapsgrenar
- 3121 Inre medicin
Citera det här
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). / Catapano, Alberico L.; Graham, Ian; De Backer, Guy; Wiklund, Olov; Chapman, M. John; Drexel, Heinz; Hoes, Arno W.; Jennings, Catriona S.; Landmesser, Ulf; Pedersen, Terje R.; Reiner, Zeljko; Riccardi, Gabriele; Taskinen, Marja-Riita; Tokgozoglu, Lale; Verschuren, W. M. Monique; Vlachopoulos, Charalambos; Wood, David A.; Luis Zamorano, Jose.
I: Atherosclerosis, Vol. 253, 10.2016, s. 281-344.Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review
TY - JOUR
T1 - 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR)
AU - Catapano, Alberico L.
AU - Graham, Ian
AU - De Backer, Guy
AU - Wiklund, Olov
AU - Chapman, M. John
AU - Drexel, Heinz
AU - Hoes, Arno W.
AU - Jennings, Catriona S.
AU - Landmesser, Ulf
AU - Pedersen, Terje R.
AU - Reiner, Zeljko
AU - Riccardi, Gabriele
AU - Taskinen, Marja-Riita
AU - Tokgozoglu, Lale
AU - Verschuren, W. M. Monique
AU - Vlachopoulos, Charalambos
AU - Wood, David A.
AU - Luis Zamorano, Jose
PY - 2016/10
Y1 - 2016/10
KW - dyslipidaemias
KW - cholesterol
KW - triglycerides
KW - low-density lipoproteins
KW - high-density lipoproteins
KW - apolipoprotein B
KW - lipoprotein remnants
KW - total cardiovascular risk
KW - treatment, lifestyle
KW - treatment, drugs
KW - treatment, adherence
KW - CORONARY-HEART-DISEASE
KW - DENSITY-LIPOPROTEIN CHOLESTEROL
KW - RANDOMIZED CONTROLLED-TRIALS
KW - HIGH-DOSE ATORVASTATIN
KW - TYPE-2 DIABETES-MELLITUS
KW - LIPID-LOWERING THERAPY
KW - CHRONIC KIDNEY-DISEASE
KW - POPULATION-BASED COHORT
KW - APOLIPOPROTEIN C-III
KW - ALL-CAUSE MORTALITY
KW - 3121 Internal medicine
U2 - 10.1016/j.atherosclerosis.2016.08.018
DO - 10.1016/j.atherosclerosis.2016.08.018
M3 - Article
VL - 253
SP - 281
EP - 344
JO - Atherosclerosis
JF - Atherosclerosis
SN - 0021-9150
ER -